(R)-9-(4-(1-(dimethylamino)propan-2-yl)phenyl)-8-hydroxy-6-methylthieno[2,3-c]quinolin-4(5H)-one hydrochloride is a potent and selective inhibitor of the protein kinase Wee1. It is commonly known as Adavosertib (AZD1775), a clinical-stage small molecule drug candidate. The compound features a complex thienoquinolinone core structure with a chiral side chain, which is crucial for its biological activity. Adavosertib functions by inhibiting the Wee1 kinase, a key regulator of the G2/M cell cycle checkpoint. By blocking Wee1, it forces cancer cells with DNA damage to enter mitosis prematurely, leading to mitotic catastrophe and cell death. This mechanism is particularly effective in p53-deficient tumors, which are reliant on the G2/M checkpoint for DNA repair. It has been extensively investigated in clinical trials, both as a monotherapy and in combination with chemotherapy or radiation, for various solid tumors including ovarian cancer, glioblastoma, and others. As an active pharmaceutical ingredient (API), it is the hydrochloride salt form of the drug substance, designed to improve solubility and stability for pharmaceutical formulation. Its synthesis involves multi-step organic chemistry, positioning key intermediates within the category of complex heterocyclic building blocks for drug development.